An interesting start to the week thanks to the weekend news. I thought there would be a little more price action after the news but it is still early and perhaps this just signals how far PCSK9 has moved from investor interest. In any case, there are some interesting pin actions from the news. 1. […]
February 9 Biotech Update
The broader market looks heavy and it appears that if we end the day red that the weekly losses will be accelerating. Markets do not bottom on a Friday, so if we cannot have a real move higher today, then we will likely be lower again to start next week. We are obviously higher to […]
Sarepta Official Statement Regarding The UK Study Halt
This morning, EP Vantage reported a temporary UK study halt in dosing after “one serious adverse event that could possibly be related to the investigational drug product” but the halt was for the UK only and did not include any other clinical trial which include Belgium, Czechia, France, Germany, Israel, Italy, Spain, Sweden, and the United States. […]
Dr. James Wilson Paper About Safety Concerns, Is Not Sarepta’s Concern!
Today morning, most of the gene-therapy stocks including SLDB, AVXS, ONCE, RGNX, BOLD, ABEO and even SRPT Stumbled following Dr. James Wilson paper published online “Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN” (link to the paper) highlighting the toxicity in NHP- non-human primate study. […]
January 26 Biotech Update
The market is relentless. Just as it is important to buy when the market seems to be going down forever, it is also important to sell on these sort of rips higher. The selling at the high levels is always more difficult for me, so I want to spend some time today talking about potential […]
January 3 Biotech Update
Yesterday had a nice start to the year, which seemed to be part of a broader rotation in the nasdaq. There was some “news” that I want to highlight but the bulk of today will be another non-consensus 2018 idea. 1. The FAERS released an update to its database of adverse events reports and it […]
Dave Trading – January 2018
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
November 20 Biotech Update
The news is winding down as we get closer to the holidays but there is some news today. For the most part, I do not expect a lot of news but there could be an M&A push to end the year if bankers need more deals for their bonuses. That being said I think we […]
November 15 Biotech Update
The sector continues to struggle and at least today we can blame the larger macro market but the fact is if the markets in general are going to correct, the sector is not going to hold up. I would not mind a broader correction as it likely would be the last leg in the biotech […]
October 27 Biotech Update
It has been an absolutely brutal earing season for the sector and for pretty good reason but you have also seen some babies being thrown out with the bathwater. Given the selling that has occurred, it is a natural reaction to assume these are buys or a bounce is coming but I prefer to sit […]
October 26 Biotech Update
A lot to discuss and I will do a couple quick hits and then focus on CELG as that seems the most fundamentally meaningful earnings report. This is going to take a couple days to really talk through all these reports but we will start with some high level points. 1. AMGN quarter was inline […]
October 25 Biotech Update
ALXN managed to hold onto its gains yesterday, which was a positive but the sector just feels heavy. I am not sure if this is simply related to nervousness over earnings plus the negative news last week or is it more macro related. The broader markets have been weakening and high volatility sectors like biotech […]
Dave-Trading November Edition
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
October 2 Biotech Update
There is not a lot of sector specific news to start the week, although there seems to be some minor news. In these situations the sector tends to follow the broader market with a slight positive bias given that it remains in a bull market. I am a little surprised that there was not a […]
September 29 Biotech Update
The sector is off to a good start but it is a relatively slow news day but the news was certainly good. It will be interesting to see how the sector closes as given the recent strength we have not seen M&A buzz and rumors take off. That is an old bull market staple with […]
A Quick Technical Look At SRPT Full Year Chart
Sarepta Therapeutics, Inc. (SRPT) Nasdaq A quick look at Sarepta’s yearly chart, from the spike to $63.73 after Exondys-51 FDA approval and the drop to $26.66 lowest point by Dec 30th, the last trading day of 2016. What is important to watch is the big picture, as we are right now above the Fibo-50% retracement […]
SRPT – Preparing For Blast Of Catalysts
Already a year has passed since Sarepta’s first drug Exondys51 was granted FDA approval on 09/19/2016. The landmark decision by Janet Woodcock, despite the review team’s opposition, gave hope to all the kids with DMD (Duchenne Muscular Dystrophy) Exondys51 is in the middle of a great launch, one of the most successful first-year launches of […]
September 6 Biotech Update
We have some more news this morning in the sector that I will focus on today. In terms of generalities, it is nice to see positive news being rewarded and while this seems like a natural state of affairs, there was a time where good news was not rewarded. The ability of positive fundamentals to […]
September 1 Biotech Update
They say that the market never bottoms on a Friday and I wonder if the same is true of topping? The sector has clearly had a strong near term move and is due for a pause but would strength today be the near term top or is there more to go? Over the longer term […]
July 24 Biotech Update
It should be a big week for news but it is starting a little slow, which is not unexpected as the earnings are clustered Tuesday through Thursday. There is some minor news to start the week but it is simply a small appetizer as to what should be a week of news. That being said […]
